HMBD-002

HMBD-002 (1-10 μg/mL) reverses VSIG3-mediated suppression of activated human PBMCs, with greater activity observed at 10 μg/mL compared to 1 μg/mL in a 1:2 VSIG3-Fc to αCD3 coating ratio assay^[1].
HMBD-002 (1-30 μg/mL) enhances immune activation in human PBMC MLRs, significantly increasing TNF-α and IFN-γ production at a concentration of 30 μg/mL^[1].
HMBD-002 inhibits the interaction between recombinant VISTA and LRIG1 proteins with an IC₅₀ of 3.4 nM^[3].
HMBD-002 (1-10 µg/mL; 24 hours at 37°C) reverses VSIG3-mediated suppression of IFN-γ secretion from anti-CD3-activated human PBMCs, with significant restoration of IFN-γ levels at 1 µg/mL and 10 µg/mL^[3].
HMBD-002 (1-30 µg/mL; 96 hours at 37°C) polarizes the immune milieu toward a proinflammatory Th1/Th17 response in human allogenic MLRs, inducing significant dose-dependent increases in IFN-γ and TNF-α and enriching proinflammatory signaling pathways at 1 µg/mL, 10 µg/mL, and 30 µg/mL^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.